Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB])

Aa, Madelon N.M. van der; Zwarthoff, Ellen C.; Steyerberg, Ewout W.; Boogaard, Merel W.; Nijsen, Yvette; Keur, Kirstin A. van der; Exsel, Antonius J.A. van; Kirkels, Wim J.; Bangma, Chris H.; Kwast, Theodorus H. van der

doi:10.1016/j.eururo.2008.05.001

Cited by 84 publications

(80 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar study conducted in the Netherlands for detection and follow-up of low-grade disease, which evaluated the value of microsatellite polymorphisms for bladder cancer detection, demonstrated sensitivity of 58% and specificity of 73% for detection of recurrence (306 ). A persistently positive test was associated with an 83% probability of recurrence at 2 years.…”

Section: Blca-4mentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 4 cancer sites—liver, bladder, cervical, and gastric—were critically reviewed. Results: α-Fetoprotein (AFP) may be used in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in patients with chronic hepatitis or cirrhosis associated with hepatitis B or C virus infection. AFP concentrations >200 μg/L in cirrhotic patients with typical hypervascular lesions >2 cm in size are consistent with HCC. After a diagnosis of HCC, posttreatment monitoring with AFP is recommended as an adjunct to imaging, especially in the absence of measurable disease. Although several urine markers have been proposed for bladder cancer, none at present can replace routine cystoscopy and cytology in the management of patients with this malignancy. Some may, however, be used as complementary adjuncts to direct more effective use of clinical procedures. Although carcinoembryonic antigen and CA 19-9 have been proposed for use gastric cancer and squamous cell carcinoma antigen for use in cervical cancer, none of these markers can currently be recommended for routine clinical use. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers for patients with liver, bladder, cervical, or gastric cancers.

show abstract

Section: Blca-4mentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

et al. 2010

View full text Add to dashboard Cite

show abstract

“…97 A recent, prospective study conducted at multiple centers showed that microsatellite analysis was a strong predictor for future recurrences but that the sensitivity was not high enough to implement its use in routine practice. 98 A more recent analytical tool that has been developed to detect genomic instability in urinary DNA uses small nucleotide polymorphisms (SNPs). SNP chips have a potential advantage over microsatellite analysis in that they can screen more than 300 genetic loci at once compared with 13-20 loci, which leads to a greater sensitivity of the detection of molecular changes.…”

Section: Tumor Biology and Markersmentioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

300

275

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

show abstract

“…[39] Microsatellite analysis has been described in the literature since 1997, and its role in detecting low-grade non-invasive bladder cancer has been evaluated. [40,41] Microsatellite analysis involves a polymerase chain reaction (PCR) recognizing tumor DNA. The findings from the latter study suggested a possible anticipatory value for this test in bladder recurrence with a recurrence rate of 83% in patients with a positive microsatellite analysis compared to only 22% in those with a negative test.…”

Section: Main Body Molecular Markers As a Diagnostic Toolmentioning

confidence: 99%

What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Abdulmajed

Sancak

Reşorlu

et al. 2014

Turkish Journal of Urology

View full text Add to dashboard Cite

Urothelial carcinoma is the 9 th most common cancer worldwide. Most urothelial tumors are non-muscle invasive on presentation. However, two-thirds of non-invasive bladder cancers will eventually recur with a 25% risk of progression to muscle-invasive bladder cancer. Tumor stage, histological grade and pathological invasion of blood vessels and lymphatic tissue are the main indicators for urothelial cancer prognosis. The gold standard for diagnosing bladder cancer is conventional white-light cystoscopy and biopsy. Urine cytology is a highly specific, sensitive test for high-grade tumors or carcinoma in situ (CIS). Urinary NMP22 has an overall sensitivity and specificity for detecting bladder cancer of 49% and 87%, respectively. However, there are falsepositive results in the presence of urinary tract infection or hematuria. The detection of specific gene mutations related to urothelial cancers has been studied and employed to reproduce markers helpful for diagnosis. According to current studies, molecular markers can be used to predict tumor recurrence. From a prognostic point of view, new molecular markers have yet to be established as reliable indicators of tumor aggressiveness. We aimed to review the molecular markers with possible prognostic significance that have been discussed in the literature. This review examined the literature for various molecular markers under development for bladder cancer in an attempt to optimize patient care and reduce the costs of treating these patients.

show abstract

Microsatellite Analysis of Voided-Urine Samples for Surveillance of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB])

Cited by 84 publications

References 25 publications

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

Bladder Cancer in 2010: How Far have We Come?

What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Contact Info

Product

Resources

About